Navigation Links
Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
Date:12/21/2007

THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1032, an oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. The initial Phase 1 clinical trial of LX1032 is planned as a double-blind, randomized, placebo-controlled, ascending single-dose study in healthy volunteers. This study is designed to evaluate the safety, tolerability, and pharmacokinetics of LX1032. Lexicon expects to initiate clinical trials with LX1032 following FDA review.

"We believe LX1032 has the potential to be an important new therapy in an area of high unmet medical need," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "LX1032 may offer important benefits to patients with carcinoid syndrome, who have very limited treatment options."

Carcinoid syndrome is the result of metastatic carcinoid tumors that usually originate from enterochromaffin cells in the lining of the gastrointestinal tract. These tumors secrete large amounts of serotonin, which causes a variety of symptoms that often includes severe diarrhea and abdominal discomfort. Carcinoid tumors are a type of neuroendocrine tumor and, according to the American Cancer Society, about 11,000 to 12,000 neuroendocrine tumors and neuroendocrine cancers are diagnosed each year in the United States. About 10% of people with carcinoid tumors will develop carcinoid syndrome.

The target for LX1032 was identified through the Genome5000(TM) project, Lexicon's program to identify the function of 5,000 druggable genes in the human genome. LX1032
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... DIEGO , May 5, 2015  A group ... formation of the Coma Research Institute, a non-profit organization ... patients and families suffering from disorders of consciousness.  ... - http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... disorder of consciousness, in which no voluntary actions can ...
(Date:5/5/2015)... SOUTH SAN FRANCISCO, Calif. , May 5, 2015 ... for the treatment of cancer, today announced that ... present at the Credit Suisse Antibody Day in ... on Wednesday, May 6. Dr. McCarthy will present an ... cancer immunotherapy and Probody drug conjugate programs. ...
(Date:5/5/2015)... 5, 2015  Indianapolis-based medical device manufacturer NICO ... line of products including the BrainPath® and Myriad™ ... deep-seated brain abnormalities and then removing affected tissue. ... more than 50 institutions throughout the ... been included in 12 abstracts, three peer-reviewed publications, ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - JSS Medical Research Inc., ... announced today that it concluded the acquisition of Max Neeman International ... . Additional regional offices are located in Ahmedabad, Bangalore ... . Through a US subsidiary, a regional office is located ... international expansion is supported by the recent equity investment transaction into ...
Breaking Biology Technology:Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
... affects the expression of genes related to the central ... Central,s open access journal Particle and Fibre Toxicology ... the nanoparticles while pregnant showed alteration in gene expression ... team of researchers from the Tokyo University of Science, ...
... ... to the slate of SDS Clinical Trials. Nissan Pilest, Medical Director of Total Dermatology in ... ... -- Well known Orange County Dermatologist and Laser Physician, Nissan Pilest , has been ...
... COPENHAGEN, Denmark, July 28 ... technology cross-licensing agreement with,GlaxoSmithKline. , ... patented technologies for rapid,synthesis and DNA-tagging of hundreds ... and the efficient screening of these,facilitating the identification ...
Cached Biology Technology:Nanotech particles affect brain development in mice 2Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division 2Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK 2
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... at the University of Cincinnati (UC) College of Medicine ... secondary stroke known as cerebral vasospasm. , A constriction ... usually occurs three to 10 days following a massive ... patients who survive the initial stroke develop vasospasm, and ...
... (Ed : testosterone isn't a protein, it's a ... allows it to function properly. Now Stanford University scientists ... when a protein molecule attached to a gold nanoparticle ... the same principle as ordinary pH tests that measure ...
... owners because of their vibrant colors. But those colors may ... For more than a century, biochemists have known that parrots ... of plumage colors, but their biochemical identity has remained elusive. ... behind the colors of parrots, describing on a molecular level ...
Cached Biology News:Researchers discover molecule that causes secondary stroke 2Scientists develop new color-coded test for protein folding 2ASU researchers finds novel chemistry at work to provide parrot's vibrant red colors 2ASU researchers finds novel chemistry at work to provide parrot's vibrant red colors 3
... Vector is specifically designed to target and ... Saccharomyces cerevisiae. Displayed proteins can be analyzed ... or putative ligands. pYD1 uses the a-agglutinin ... domains Aga1 and Aga2 to display recombinant ...
... Aph-1a (Aph-1aL,S Loop 92-115), O2F1 Affinity ... a multiprotein complex consisting of presenilin, ... proteins are necessary for full proteolytic ... cleavage of a number of integral ...
TGase3 (S-20)...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Biology Products: